Title: Natural Antisense and Non-Coding RNA Transcripts as Drug Targets
Patent Number: 8,288,354
Filed: Dec. 28, 2006
Inventor: Claes Wahlestedt, Scripps Research Institute (Opko Health)
“Small interfering RNA knock down antisense transcripts, and regulate the expression of their sense partners,” the patent's abstract states. “This regulation can either be discordant — antisense knockdown results in sense transcript elevation — or concordant — antisense knockdown results in concomitant sense transcript reduction.”
Title: siRNA Specific to WT1 17AA(-) Isoform and Use Thereof
Patent Number: 8,288,355
Filed: March 28, 2007
Lead Inventor: Haruo Sugiyama, International Institute of Cancer Immunology
The invention, the patent's abstract states, comprises an siRNA that acts as a “cancer cell-specific molecular-targeted therapy, which successfully controls the function of WT1.”
Title: microRNAs
Patent Number: 8,288,356
Filed: Oct. 3, 2008
Lead Inventor: Susanna Obad, Santaris Pharma
The invention relates to “very short, heavily modified oligonucleotides [that] target and inhibit microRNAs in vivo and their use in medicaments and pharmaceutical compositions,” according to the patent's abstract.
Title: Use of Inhibitors of Leukotriene B4 Receptor BLT2 for Treating Human Cancers
Patent Number: 8,288,357
Filed: March 24, 2008
Lead Inventor: Jae-Hong Kim, Korea University Research & Business Foundation
The invention relates to a “pharmaceutical composition for treating human cancers comprising BLT2 inhibitors and a method for treating human cancers using BLT2 inhibitors,” the patent's abstract states. “BLT2 has an important role in metastasis of cancer cells and angiogenesis of tumor and ... the anti-cancer activity of the BLT2 inhibitors is accomplished by inducing the apoptosis of cancer cells, inhibiting the metastasis of cancer cells, or inhibiting the angiogenesis of tumor.”
The patent specifically claims BLT2-targeted siRNAs.
Title: Therapeutic Targets and Molecules
Patent Number: 8,288,358
Filed: March 26, 2008
Lead Inventor: Paul Stephen Foster, Newcastle Innovation
“The invention provides methods and compositions for treating or preventing inflammation or an inflammatory condition in a subject, comprising administering to the subject an effective amount of at least one antagonist of one or more [microRNA] up-regulated in inflammatory disease conditions and response to allergen challenge,” the patent's abstract states. “The invention also provides methods for diagnosing inflammatory conditions based on miRNA expression profile signatures.”
Title: Compositions and Methods for Inhibiting Expression of CD45 Gene
Patent Number: 8,288,525
Filed: Oct. 27, 2010
Lead Inventor: Antonin de Fougerolles, Alnylam Pharmaceuticals
“The invention relates to a double-stranded ribonucleic acid for inhibiting the expression of the CD45 gene,” according to the patent's abstract.
Title: Method of Delivering RNA Interference and Uses Thereof
Application Number: 20120258534
Filed: March 29, 2012
Lead Inventor: Judy Lieberman, Immune Disease Institute (Harvard University)
The invention, the patent application's abstract states, comprises “contacting the cell with a fusion protein-double-stranded RNA complex, the complex comprising ... a double-stranded RNA of interest and a fusion protein.” The fusion protein comprises a “targeting moiety, which will specifically bind to a site on a target cell, and a binding moiety, which will bind to the double-stranded RNA.”
Title: Methods and Compositions for the Specific Inhibition of Gene Expression by Double-Stranded RNA
Application Number: 20120258535
Filed: June 8, 2012
Lead Inventor: John Rossi, City of Hope (Integrated DNA Technologies)
“The invention is directed to compositions and methods for selectively reducing the expression of a gene product from a desired target gene in a cell, as well as for treating diseases caused by the expression of the gene,” the patent application's abstract states. “More particularly, the invention is directed to compositions that contain double-stranded RNA, and methods for preparing them, that are capable of reducing the expression of target genes in eukaryotic cells. The dsRNA has a first oligonucleotide sequence that is between 25 and about 30 nucleotides in length and a second oligonucleotide sequence that anneals to the first sequence under biological conditions. In addition, a region of one of the sequences of the dsRNA having a sequence length of at least 19 nucleotides is sufficiently complementary to a nucleotide sequence of the RNA produced from the target gene to trigger the destruction of the target RNA by the RNAi machinery.”
Title: siRNA Targeting Proto-Oncogene MET
Application Number: 20120258888
Filed: June 12, 2012
Lead Inventor: Anastasia Khvorova, Dharmacon (Thermo Fisher Scientific)
“Efficient sequence-specific gene silencing is possible through the use of siRNA technology,” the patent application's abstract states. “By selecting particular siRNAs by rational design, one can maximize the generation of an effective gene-silencing reagent, as well as methods for silencing genes. Methods, compositions, and kits generated through rational design of siRNAs are disclosed including those directed to nucleotide sequences for MET.”
Title: siRNA Targeting Kinase Insert Domain Receptor
Application Number: 20120258889
Filed: June 15, 2012
Lead Inventor: Anastasia Khvorova, Dharmacon (Thermo Fisher Scientific)
“Efficient sequence-specific gene silencing is possible through the use of siRNA technology,” the patent application's abstract states. “By selecting particular siRNAs by rational design, one can maximize the generation of an effective gene-silencing reagent, as well as methods for silencing genes. Methods, compositions, and kits generated through rational design of siRNAs are disclosed including those directed to nucleotide sequences for KDR.”
Title: Duplex Oligonucleotides with Enhanced Functionality in Gene Regulation
Application Number: 20120259001
Filed: April 30, 2012
Lead Inventor: Anastasia Khvorova, Dharmacon (Thermo Fisher Scientific)
The invention, the patent application's abstract states, comprises “methods of enhancing functionality of duplex oligonucleotides and compositions made by the methods. The duplex oligonucleotides include siRNAs, miRNA mimics, and piRNA mimics [that] contain modified nucleotides and mismatches between the two strands of the molecule at specific nucleotide positions.”